⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
FATE News
Fate Therapeutics, Inc.
RARE Drug Development Symposium Marks 10th Anniversary with Dedicated Pitch Sessions and The Theme and Call to Action to Align Advocates, Science and Industry
prnewswire.com
BIIB
REGN
GILD
BTE
BROS
BFLY
BCTX
BCRX
BTAI
ALRS
CAPR
CRIS
CYCN
EXAS
FATE
GNTX
HRMY
INCY
IONS
KODK
LAKE
LULU
MRNA
NBIX
NTRA
OCGN
ORGN
PGEN
PLRX
RARE
RGNX
RXRX
SAVA
SGMO
SNOW
SRPT
STEM
TGTX
TLSA
TXG
VRTX
ZETA
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
globenewswire.com
FATE
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
globenewswire.com
FATE
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences
globenewswire.com
FATE
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
prnewswire.com
CMPX
NKTX
GTBP
RXRX
FATE
Form 8-K
sec.gov
FATE
Fate Therapeutics Appoints Laura Hamill to Board of Directors
globenewswire.com
FATE
After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
globenewswire.com
GTBP
FATE
NKTX
CMPX
CRBU
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
globenewswire.com
IOVA
GTBP
NKTX
IBRX
FATE
Form 8-K
sec.gov
FATE